CRC Research Update — August 06, 2026
Today's colorectal cancer research highlights
Curated CRC research — accessible, accurate, actionable
The CRC Digest
Thursday, August 06, 2026
IMPORTANT: The CRC Digest curates and summarizes publicly available research for informational and educational purposes only. Nothing in this newsletter constitutes medical advice, diagnosis, or treatment recommendation. The information provided should not be used as a substitute for professional medical advice. Always seek the guidance of your physician or other qualified health provider with any questions regarding a medical condition or treatment. Content is generated with AI assistance and reviewed by the editorial team. We are not medical professionals. Individual results, treatments, and outcomes vary.
CRC Research Update
-
RESEARCH
KRAS Mutation Subtypes May Influence Response to Neoadjuvant Therapy in Rectal CancerA meta-analysis investigated whether different KRAS mutation subtypes affect pathological complete response rates after neoadjuvant chemoradiotherapy in locally advanced rectal cancer. The study examined KRAS mutations within and outside exon 2. (BJS Open)
-
SCREENING
Study Examines Universal Tumor Screening for Lynch Syndrome in JapanA prospective study of 591 patients with stage II/III colorectal cancer in Japan aimed to clarify the clinical utility and cost-effectiveness of universal tumor screening using immunohistochemistry to identify Lynch syndrome, with implications for screening strategies in different populations. (International Journal of Clinical Oncology)
Research continues to advance our understanding of personalized treatment and early detection strategies. Stay informed and discuss new findings with your care team.
Get CRC research intelligence delivered weekly — free.
SubscribeCRC Digest
Not Medical Advice
The CRC Digest provides research summaries for informational and educational purposes only. This is not medical advice. Always consult your healthcare provider before making any decisions about your care.
Content is curated with AI assistance and reviewed by the editorial team.
Browse Past Issues · Read our full disclaimer · Manage subscription
Useful? Forward it to a colleague. Every topic in this briefing has a live research dossier — trajectory and evidence — at Signal Bureau.
Got this from a colleague? Subscribe here — we only ever add readers who sign themselves up.
Evolution Accelerator, Inc. (dba Evolution Labs) · 3941 Park Dr., Suite 20341, El Dorado Hills, CA 95762
You are receiving this because you subscribed to CRC Digest (self-serve signup)
Unsubscribe — honored promptly, no login required. · Privacy policy · Manage or delete your data